Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU)

Overview

Journal Mol Front J

Specialty Molecular Biology

Date 2020 Jun 12

PMID 32524084

Authors

Cary O Harding

Affiliations

Soon will be listed here.

Abstract

Phenylketonuria (PKU) due to recessively inherited phenylalanine hydroxylase (PAH) deficiency is among the most common inborn errors of metabolism. Dietary therapy begun early in infancy prevents the major manifestations of the disease but shortcomings to treatment continue to exist including lifelong commitment to a complicated and unpalatable diet, poor adherence to diet in adolescence and adulthood, and consequently a range of unsatisfactory outcomes, including neuropsychiatric disorders, frequently develop. Novel treatments that do not strictly depend upon dietary protein restriction are actively sought. This review discusses the potential for and the limitations of permanently curative cell-directed treatment of PKU, including liver-directed gene therapy and gene editing, if initiated during early infancy. A fictional but realistic vignette of a family with a new baby girl recently diagnosed with PKU is presented. What is needed to permanently cure her?

References

Platt L, Koch R, Hanley W, Levy H, Matalon R, Rouse B . The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am J Obstet Gynecol. 2000; 182(2):326-33. DOI: 10.1016/s0002-9378(00)70219-5. View

Levy H, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz F . Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007; 370(9586):504-10. DOI: 10.1016/S0140-6736(07)61234-3. View

McDonald J, Bode V, Dove W, Shedlovsky A . Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. Proc Natl Acad Sci U S A. 1990; 87(5):1965-7. PMC: 53605. DOI: 10.1073/pnas.87.5.1965. View

Hamman K, Clark H, Montini E, Al-Dhalimy M, Grompe M, Finegold M . Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Mol Ther. 2005; 12(2):337-44. PMC: 2694052. DOI: 10.1016/j.ymthe.2005.03.025. View

Harding C, Amato R, Stuy M, Longo N, Burton B, Posner J . Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol Genet Metab. 2018; 124(1):20-26. DOI: 10.1016/j.ymgme.2018.03.003. View

Laconi E, Laconi S . Principles of hepatocyte repopulation. Semin Cell Dev Biol. 2002; 13(6):433-8. DOI: 10.1016/s1084952102001313. View

Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B . Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis. 2002; 25(5):333-46. DOI: 10.1023/a:1020158631102. View

Choukair D, Kneppo C, Feneberg R, Schonau E, Lindner M, Kolker S . Analysis of the functional muscle-bone unit of the forearm in patients with phenylketonuria by peripheral quantitative computed tomography. J Inherit Metab Dis. 2016; 40(2):219-226. DOI: 10.1007/s10545-016-0002-6. View

Manti F, Nardecchia F, Chiarotti F, Carducci C, Carducci C, Leuzzi V . Psychiatric disorders in adolescent and young adult patients with phenylketonuria. Mol Genet Metab. 2015; 117(1):12-8. DOI: 10.1016/j.ymgme.2015.11.006. View

10.

Hanley W, Feigenbaum A, Clarke J, Schoonheyt W, Austin V . Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. Eur J Pediatr. 1996; 155 Suppl 1:S145-7. DOI: 10.1007/pl00014233. View

11.

Horslen S, McCowan T, Goertzen T, Warkentin P, Cai H, Strom S . Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics. 2003; 111(6 Pt 1):1262-7. DOI: 10.1542/peds.111.6.1262. View

12.

HORNER F, STREAMER C . Effect of a phenylalanine-restricted diet on patients with phenylketonuria; clinical observations in three cases. J Am Med Assoc. 1956; 161(17):1628-30. DOI: 10.1001/jama.1956.62970170004005b. View

13.

Hamman K, Winn S, Harding C . Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU). Mol Genet Metab. 2011; 104(3):235-40. PMC: 3219060. DOI: 10.1016/j.ymgme.2011.07.027. View

14.

Lichter-Konecki U, Hipke C, Konecki D . Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. Mol Genet Metab. 1999; 67(4):308-16. DOI: 10.1006/mgme.1999.2880. View

15.

Bilder D, Kobori J, Cohen-Pfeffer J, Johnson E, Jurecki E, Grant M . Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study. Mol Genet Metab. 2017; 121(1):1-8. DOI: 10.1016/j.ymgme.2017.03.002. View

16.

Blainey J, GULLIFORD R . Phenylalanine-restricted diets in the treatment of phenylketonuria. Arch Dis Child. 1956; 31(160):452-66. PMC: 2012011. DOI: 10.1136/adc.31.160.452. View

17.

Anikster Y, Haack T, Vilboux T, Pode-Shakked B, Thony B, Shen N . Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability. Am J Hum Genet. 2017; 100(2):257-266. PMC: 5294665. DOI: 10.1016/j.ajhg.2017.01.002. View

18.

Adamczyk P, Morawiec-Knysak A, Pludowski P, Banaszak B, Karpe J, Pluskiewicz W . Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria. J Bone Miner Metab. 2010; 29(2):236-44. DOI: 10.1007/s00774-010-0216-x. View

19.

Darling G, Mathias P, ORegan M, Naughten E . Serum selenium levels in individuals on PKU diets. J Inherit Metab Dis. 1992; 15(5):769-73. DOI: 10.1007/BF01800019. View

20.

WOOLF L, Griffiths R, Moncrieff A . Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J. 1955; 1(4905):57-64. PMC: 2060789. DOI: 10.1136/bmj.1.4905.57. View